Regeneron Pharmaceuticals beat Wall Street estimates for second-quarter revenue and profit on Friday helped by robust demand ...

Sanofi CEO Paul Hudson joins 'Squawk Box' to discuss the company's quarterly earnings results, Blueprint acquisition, strong ...

France's Sanofi said on Thursday that it expects annual sales to grow by high single-digit percentage, helped by strong ...

On Friday, Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) reported second-quarter adjusted earnings of $12.89 per share, up 12% ...

Sanofi rode the growing sales wave for blockbuster immunology drug Dupixent (dupilumab) in Q2 but reported ...

The pharmaceutical company’s top line grew faster than analysts expected for the second quarter due to drug launches and ...

Developed using Regeneron's VelocImmune technology, Dupixent is a fully human monoclonal antibody that blocks the interleukin-4 (IL4) and interleukin-13 (IL13) signalling pathways.

Dupixent, a Sanofi and Regeneron Pharmaceuticals drug, is now approved for chronic obstructive pulmonary disease (COPD), a progressive lung disease prevalent in smokers. It’s the sixth FDA ...

Viking Therapeutics ' ( VKTX 0.28%) shares could rise over the next year by as much as 165% at the midpoint according to some ...

DUPIXENT may also help reduce the amount of oral corticosteroids you need while preventing severe asthma attacks and improving your breathing. DUPIXENT is not used to treat sudden breathing problems.

Dupixent, an interleukin-4 receptor alpha antagonist, is the first treatment indicated for prurigo nodularis. Credit: Getty Images. The Food and Drug Administration (FDA) has approved Dupixent ...